## Generation of cytotoxic T lymphocytes (CTL) in vitro and tumor-rejection responses by sensitization of semi-syngeneic mice with tumor-antigen-reconstituted liposomes were investigated. Liposomes were prepared from a crude butanol extract (CBE) of BALBRVD leukemia cells and egg phosphatidylcholi
Human anti-lymphoma responses generated in vitro and in vivo following sensitization with allogeneic leukocytes
β Scribed by Joyce M. Zarling; Neil E. Kay; Barbara Grant; Masaki Yasukawa; Fritz H. Bach
- Book ID
- 104660429
- Publisher
- Springer-Verlag
- Year
- 1983
- Tongue
- English
- Weight
- 338 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
β¦ Synopsis
Peripheral blood lymphocytes (PBL) from a patient with poorly differentiated lymphocyte lymphoma (PDLL), after stimulation for 7 days with X-irradiated allogeneic lymphocytes pooled from three or ten donors (pool~), were cytotoxic for autologous lymphoma cells. Some clones lytic for autologous lymphoma cells, that were derived from this patient's pool-stimulated cells, resembled cytotoxic T lymphocytes (CTL), while other clones resembled natural killer (NK)-like cells in that they also lysed NK-sensitive HLA-negative K562 cells. In a second patient with more advanced PDLL, PDL cultured with T-cell growth factor (which is produced following stimulation with mitogens or alloantigens) lysed autologous lymphoma cells. On the basis of these in vitro findings, we asked whether IV transfusions with X-irradiated allogeneic leukocytes would result in anti-lymphoma responses in vivo. Ten days after transfusions with X-irradiated leukocytes from four unrelated donors, the first patient's two previously palpable nodes were no longer palpable and he remained in complete clinical remission for 6 months. The second patient had a temporary partial remission with dramatic reduction in size of multiple cervical and axillary nodes within 2 weeks after receiving the leukocyte transfusions.
π SIMILAR VOLUMES
## Abstract CD19 is an attractive therapeutic target for treating human Bβcell tumors. In our study, chimeric (c) divalent (cHD37) and tetravalent (cHD37βDcVV) antiβCD19 monoclonal antibodies (MAbs) were constructed, expressed and evaluated for their binding to human 19βpositive (CD19^+^) tumor cel